(Health-NewsWire.Net, August 24, 2016 ) Lixte Biotechnology Holdings, Inc. (LIXT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by Publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description - A detailed description of the company's operations and business divisions. - Corporate strategy - Analyst's summarization of the company's business strategy. - SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats. - Company history - Progression of key events associated with the company. - Major products and services - A list of major products, services and brands of the company. - Key competitors - A list of key competitors to the company. - Key employees - A list of the key executives of the company. - Executive biographies - A brief summary of the executives' employment history. - Key operational heads - A list of personnel heading key departments/functions. - Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities - A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Free sample brochure @ http://www.reportsweb.com/Lixte-Biotechnology-Holdings,-Inc.-(LIXT)---Strategic-and-Financial-SWOT-Analysis-Review
Highlights
Lixte Biotechnology Holdings, Inc. (Lixte) is a clinical stage pharmaceutical company, which focuses on the discovery of novel drugs for the treatment of cancer and non-malignant diseases. It develops comprises two classes of drugs, namely, protein phosphatase inhibitors (PTase-i) designated as the LB-100 series; and histone deacetylase inhibitors (HDACi), designated as the LB-200 series of compounds. The company's product pipeline comprises drug candidates for the treatment of cancer and neurodegenerative disorders such as solid tumors, acute ischemia and Gaucher's disease, among others. Its lead compound, LB-100 is being developed in Phase I clinical trials. Lixte established a cooperative research and development agreement with National Institute of Neurological Disorders and Stroke of the National Institutes of Health for development of its anti-cancer treatments. Lixte is headquartered in New York, the US.
Lixte Biotechnology Holdings, Inc. Key Recent Developments
Jun 07, 2016: Dr. Stephen Forman Joins Lixte Biotechnology's Board of Directors
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance. - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research. - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Discount Copy is available @ http://www.reportsweb.com/inquiry&RW0001316920/discount About Us ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. Contact Us: Phone: +1-646-491-9876 Email: sales@reportsweb.com
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|